lubiprostone
Commercial- Indications
- Chronic idiopathic constipation, Constipation-predominant irritable bowel syndrome
Company intelligence / Profile preview
Sucampo
Rockville, Maryland, United Stateswww2.mallinckrodt.com ↗
- Ownership
- Private
- Employees
- ~225
- Development stage
- Commercial
01
Overview
Sucampo had two marketed products—AMITIZA (lubiprostone) for various forms of constipation and RESCULA (unoprostone isopropyl) for ocular hypertension/glaucoma. At the time of its acquisition by Mallinckrodt in 2018, it had late-stage programs including VTS‑270 for Niemann-Pick Disease Type C and CPP‑1X/sulindac for familial adenomatous polyposis, both in Phase 3 trials[9][2][6].
- Therapeutic areas
- GastroenterologyOphthalmologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Takeda Pharmaceutical Company – global licensing/distribution rights to AMITIZA except US/Canada/Japan/ChinaCancer Prevention Pharmaceuticals – collaboration on FAP programSanten Pharmaceutical Co., Ltd. – commercialization of RESCULA in JapanZuellig Pharma Inc. – Taiwan distribution[5][6]
Beyond the preview
Go deeper on Sucampo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sucampo.